References
NSCLC
NON-SMALL CELL LUNG CANCER, NSCLC
Schematic overview of study design and principal component analysis (PCA) of all samples, not pretreated with corticosteroids, at all analyzed time points. Mitazalimab induced a transient shift along both principal components (PC1 and PC2) which was most predominant at 600 µg/kg and 900 µg/kg. Colors indicate mitazalimab dose, and PC1 and PC2 explain 25% and 13% variance, respectively.Pharmacodynamic effects on peripheral transcriptome induced by mitazalimab at 600 µg/kg and 900 µg/kg: (RNA sequencing data allowed for patient stratification with distinct mitazalimab-induced transcriptomic alterations in the patient groups: (Mitazalimab-induced immune activation in patient groups stratified based on peripheral transcriptomic alterations: (Demographics and baseline clinical characteristics of all included patients.* Subset of patients included in Phase I trial NCT02829099; NSCLC: non-small cell lung cancer.